Neuroprotection of Pioglitazone in Acute Ischemic Stroke
Status:
Terminated
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Pioglitzone, an oral anti-diabetic drug which can reduce insulin resistance and decrease
inflammation. It has been proven to be an effective neuroprotective agent in animal model of
ischemic stroke. In this study, the investigators will conduct a phase II clinical trial
(double-blind, randomized placebo controlled study) to survey the neuroprotection effect of
pioglitazone in stroke patients with hyperglycemia. A total of 152 acute ischemic stroke
patients with hyperglycemic will receive insulin or sulfonyurea for blood sugar control, and
will be randomly randomized into intervention (Pioglitazone 30mg once a day p.o,) and control
group (placebo). The investigators expect to prove the neuroprotective efficacy of
Pioglitazone in acute stroke with hyperglycemia and identify the biomarkers associated with
good neurological outcome in patients with Pioglitazone treatment from the investigators
clinical trial.